BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 22, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» TEV-56278 demonstrates tumor regression and long-term antitumor immunity in murine models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
TEV-56278 demonstrates tumor regression and long-term antitumor immunity in murine models
Nov. 15, 2024
No Comments
At the recent SITC meeting in Houston, Teva Pharmaceutical Industries Ltd. reported preclinical data for the fusion protein TEV-56278, which is in phase I development.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Immuno-oncology